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Severe alcoholic hepatitis (sAH) is associated with a poor prognosis. There is no proven effective treatment for sAH,
which is why early transplantation has been increasingly discussed. Hepatoblastoma-derived C3A cells express antiinﬂammatory proteins and growth factors and were tested in an extracorporeal cellular therapy (ELAD) study to establish
their effect on survival for subjects with sAH. Adults with sAH, bilirubin 8 mg/dL, Maddrey’s discriminant
function  32, and Model for End-Stage Liver Disease (MELD) score £ 35 were randomized to receive standard of care
(SOC) only or 3-5 days of continuous ELAD treatment plus SOC. After a minimum follow-up of 91 days, overall survival (OS) was assessed by using a Kaplan-Meier survival analysis. A total of 203 subjects were enrolled (96 ELAD and
107 SOC) at 40 sites worldwide. Comparison of baseline characteristics showed no signiﬁcant differences between groups
and within subgroups. There was no signiﬁcant difference in serious adverse events between the 2 groups. In an analysis
of the intent-to-treat population, there was no difference in OS (51.0% versus 49.5%). The study failed its primary and
secondary end point in a population with sAH and with a MELD ranging from 18 to 35 and no upper age limit. In the
prespeciﬁed analysis of subjects with MELD < 28 (n 5 120), ELAD was associated with a trend toward higher OS at 91
days (68.6% versus 53.6%; P 5 .08). Regression analysis identiﬁed high creatinine and international normalized ratio, but
not bilirubin, as the MELD components predicting negative outcomes with ELAD. A new trial investigating a potential
beneﬁt of ELAD in younger subjects with sufﬁcient renal function and less severe coagulopathy has been initiated.
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Severe alcoholic hepatitis (sAH), a syndrome which
occurs in persons with heavy alcohol abuse, typically
presents as liver failure with jaundice and coagulopathy.(1) After initial presentation of sAH (Maddrey’s
discriminant function [DF]  32), mortality varies
between 40% and 60% depending on the presence of
secondary organ complications and treatment.
The pathogenesis of liver failure in alcoholic hepatitis (AH) is complex and includes hepatic steatosis
associated with inﬂammation, hepatocellular damage,
and rapid cholestasis. Increased translocation of the
gut due to excessive alcohol is thought to exacerbate
inﬂammation in acute events, creating a vicious cycle,
where inﬂammation, oxidative stress, and cholestatic
toxin accumulation with consequent cellular damage
perpetuate each other.(2-4)
Currently, treatment of sAH uses medical therapy
with an anti-inﬂammatory or immunosuppressive regimen.(3) A recent study, steroids or pentoxifylline for
alcoholic hepatitis (STOPAH), aimed to show the
effectiveness of the current methods of treating sAH

Abbreviations: AASLD, American Association for the Study of Liver
Diseases; AH, alcoholic hepatitis; ALT, alanine transaminase; AST,
aspartate transaminase; CI, conﬁdence interval; CT, computed
tomography; DF, discriminant function; DIC, disseminated intravascular coagulation; DSMB, data and safety monitoring board;
EASL, European Association for the Study of the Liver; ELAD,
extracorporeal cellular therapy; HR, hazard ratio; IL1Ra, interleukin
1 receptor antagonist; INR, international normalized ratio; ITT,
intent-to-treat; MELD, Model for End-Stage Liver Disease; OS,
overall survival; PEth, phosphatidyl ethanol; sAH, severe alcoholic
hepatitis; SD, standard deviation; SOC, standard of care; STOPAH,
steroids or pentoxifylline for alcoholic hepatitis; TEAE, treatmentemergent adverse event; TESAE, treatment-emergent serious adverse
event; UF, ultraﬁltrate; WBC, white blood cell.
Address reprint requests to Jan Stange, M.D., Center for Internal
Medicine, University of Rostock, E-Heydemann Strasse 06, Rostock
18055, Germany. E-mail: jan.stange@med.uni-rostock.de
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Asrani, Nikunj Shah, Paul Gaglio, Anupama Duddempudi, Brian
Borg, Rajiv Jalan, Robert Brown, Heather Patton, Rohit Satoskar,
Simona Rossi, Amay Parikh, Ahmed ElSharkawy, Parvez Mantry,
Linda Sher, David Wolf, Marquis Hart, Charles Landis, Alan Wigg,
Shahid Habib, Geoffrey McCaughan, Steven Colquhoun, and the
VTI-208 Study Group.
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using prednisolone and/or pentoxifylline(5) and showed
no overall impact on 90-day survival.(5) Because these
results suggest no longterm survival increase from
treatment with glucocorticoids, controversy exists
regarding the beneﬁts of these drugs in the sAH population because these patients are often at high risk of
gastrointestinal bleeds or sepsis, complications that
could be exacerbated by steroids.(5-7) Increasingly,
nonresponders to medical therapy are considered to be
candidates for early transplantation(8,9) because the
majority of these patients will not survive a 6-month
period of alcohol abstinence required by common
protocols.(10)
However, to narrow the use of the limited organ
pool, cellular therapies have been suggested as an alternative option to current medical treatment for sAH by
providing anti-inﬂammatory effects and promoting
hepatocellular regeneration.(11,12)
The concept of liver cell therapy in sAH is based on
the assumption that by providing hepatocellular support, the impaired liver cells can recover, inhibiting
further degeneration and enabling recovery.
A proteomic analysis of C3A cell products identiﬁed numerous proteins with anti-inﬂammatory properties, such as interleukin 1 receptor antagonist
(IL1Ra), the expression of which could be stimulated
by various proinﬂammatory cytokines elevated in
AH.(13) Also C3A cells have been shown to express
antiapoptotic and anti-oxidative mechanisms that
could further dampen the hepatocellular injury caused
by inﬂammation and oxidative stress. In addition,
C3A cells express several growth factors, such as transforming growth factor, vascular endothelial growth factor, and so on, involved in the natural regeneration
naturally following the acute phase response as the ﬁrst
line of response to injury.(14)
In a prior phase 2 study, VTI-206, C3A cellular
therapy did not show survival beneﬁt in end-stage liver
disease but a positive trend toward improved survival
in a subset of sAH patients.(15) The VTI-208 study
(NCT01471028) was conducted to evaluate the safety
and efﬁcacy of ELAD with respect to overall survival
(OS) of subjects with sAH.

Patients and Methods
PARTICIPANTS
Subjects 18 years of age with a medical history of
heavy alcohol abuse with a maximum of 6 weeks
between the last intake of alcohol and rapid onset of
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jaundice (serum bilirubin  8 mg/dL) and coagulopathy (Maddrey’s DF  32) were enrolled in VTI-208.
Stratum A was populated with subjects who had
either liver biopsy–conﬁrmed sAH or 2 of the following:
hepatomegaly, AST > ALT, leukocytosis, or ascites.
Subjects with sAH and underlying chronic liver disease other than alcoholic liver disease documented by

The statistical analysis was carried out according to a prespecified statistical plan, submitted to the FDA before the end of the study by
Sara Rhee from Synteract, Inc. Carlsbad, CA. The article was also
reviewed and edited by Michael Millis, Robert Ashley, William Frank,
and Andrew Henry, who were all material in the operational aspects
of the study.
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from Ocera. Michael Millis owns stocks in and consults for Vital
Therapies. Lewis Teperman and Michael Millis are members of the
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Rajiv Jalan advises and received grants from Ocera. He is on the
speakers’ bureau of and received grants from Grifols and Sequana.
Tarek Hassanein advises, is on the speakers’ bureau of, and recieved
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liver biopsy, laboratory ﬁndings, and/or a medical history were randomized in a separate stratum B.
Patients with end-stage cirrhosis, as indicated by
craniocaudal liver size <10 cm on ultrasound, liver
volume <750 cc on computed tomography (CT) or
magnetic resonance imaging, or portal vein thrombosis, were excluded. Also excluded were patients with
Model for End-Stage Liver Disease (MELD) > 35,
platelets < 40,000/mm3, and individuals with severe
concomitant diseases, uncontrolled bleeding, infection
that was clinically unresponsive to antibiotics, hemodynamic instability, or those on chronic dialysis.

STUDY DESIGN
In this open-label trial, subjects were randomized to
either receive standard of care (SOC) as deﬁned by the
American Association for the Study of Liver Disease
(AASLD) and the European Association for the Study of
the Liver (EASL) guidelines (control group) or SOC
plus ELAD. ELAD treatment consisted of drawing
blood from the subject via a dual-lumen catheter using an
extracorporeal pumping unit and then separating the
plasma ﬂuid (ultraﬁltrate [UF]) from the cellular components using a speciﬁcally designed UF generator cartridge.
While the cellular components are returned to the subject
via the venous access, the UF is circulated at a high ﬂow
rate through 4 metabolically active hollow-ﬁber ELAD
cartridges containing approximately 440 g of C3A cells.
After circulation through the cartridges, the UF passes
through a 0.2-mm pore-size ﬁlter, is recombined with the
cellular components of the subject’s blood, and is returned
to the subject through the dual-lumen catheter (Fig. 1).
For anticoagulation, site-based protocols for continuous
hemoﬁltration were used, with the exception of citrate.
ELAD treatment was conducted continuously for
120 hours unless subjects deteriorated and became
futile, withdrew consent, or subjects responded quickly
after 72 hours.
Subjects were followed for at least 91 days after randomization of the last subject.
During that time, subjects had daily visits the ﬁrst
week unless discharged and then at days 7, 14, 21, 28,
63, and 91.
To ensure unbiased medical management, health
assessments during the follow-up period were performed by an independent physician/nurse practitioner applying SOC. All subjects received weekly
home health care service visits that included weight
measurement, nutritional consultation, and a blinded
phosphatidyl ethanol (PEth) to detect posttreatment
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FIG. 1. The ELAD system is an extracorporeal human hepatic cell-based liver treatment. During ELAD treatment, blood is drawn
from the subject via a dual-lumen catheter using an extracorporeal pumping unit, and then is separated by a speciﬁcally designed UF
generator cartridge. The UF contains proteins the size of albumin and smaller but does not contain larger proteins such as antibodies.
The UF is circulated at a high ﬂow rate through the ELAD cartridges, which contain approximately 440 g of C3A cells. After circulation through the ELAD cartridges, the UF passes through a 0.2-mm pore size cell ﬁlter, is recombined with the cellular components
of the subject’s blood, and is then returned to the subject via the dual-lumen catheter.


alcohol use. Upon initiation of the VTI-208 study,
subjects also consented and were enrolled into an
extension study, VTI-208E to follow-up for 5 years
to assess the continued survival of both arms.
The study was approved by all institutional review
boards/ethics committees, and written informed consents were obtained from all participants or participants’ legally authorized representative.

providing additional survival data up to a maximum of 5
years. The secondary objectives were to evaluate the proportion of survivors at study days 28 and 91.

OBJECTIVES

ASSESSMENT OF SAFETY

The primary objective of the study was to evaluate safety
and efﬁcacy of ELAD with respect to OS up to at least
study day 91, with follow-up protocol VTI-208E

Treatment-emergent adverse events (TEAEs) and
treatment-emergent serious adverse events (TESAEs)
were documented for both arms of the study

ASSESSMENT OF EFFICACY
OS was assessed using a Kaplan-Meier survival analysis of
the intent-to-treat (ITT) population using a log-rank test.
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population. For events occurring in ELAD subjects,
the investigator assessed a potential relationship with
the ELAD treatment. All TESAEs during the study
were reviewed by an independent data and safety monitoring board (DSMB).

LABORATORY TESTING
Standard blood testing was used to measure total bilirubin, international normalized ratio (INR), and creatinine for the calculation of MELD score. The site’s
certiﬁed clinical laboratories were also responsible for
collecting all blood cell counts and other biochemistry
data that were needed at baseline and follow-up visits.

STANDARD OF CARE
Trial sites were instructed to apply AASLD/EASL
guidelines for treatment of complications of liver disease. For speciﬁc sAH SOC, concomitant medication,
such as steroids, pentoxifylline, N-acetylcysteine, and
antibiotics were documented.

RANDOMIZATION
Randomization was conducted using a predetermined
block size (4) with a 1:1 ratio of ELAD to control subjects. Separate randomization schedules (stratiﬁed randomization) were made for strata A and B. The
allocation concealment was computerized based on an
electronic case report ﬁle system. Once a subject was
enrolled in the study, the principal investigator
received a code from the sponsor’s enrollment hotline
and randomization occurred online.

STATISTICAL METHODS

Power Calculation
On the basis of a former controlled study, 40% of control subjects and 60% of ELAD-treated subjects were
expected to survive at least until day 91.(15) Under the
assumption of a proportional hazards model, this
leads to median survival estimates of approximately 68
days and 122 days for control and ELAD subjects,
respectively.
A sample size of 100 subjects per group was calculated to provide a power of at least 0.95 using a logrank test comparing 2 survival curves with a minimum
of 91-day follow-up for the last subject enrolled. No
interim analysis was performed.
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Primary Analysis
The OS of the ITT population was done by KaplanMeier analysis using a log-rank test to evaluate the null
hypothesis of equality of survival curves with a minimum follow-up of 91 days after the enrollment of the
last subject.
Model-based estimates (and conﬁdence limits) of
median survival by treatment group and hazard rates,
along with the hazard ratio (HR) and conﬁdence interval (CI), were produced.

Secondary Analyses
A chi-square test was used to evaluate the proportion
of subjects who survived at the end of study day 28 and
the end of study day 91 based on the ITT population.

Comparability of Groups
Demographics and baseline parameters were compared
with the 2 groups by exact chi-square methods for
discrete variables and parametric (t test) or nonparametric (Mann-Whitney U) comparisons for continuous variables.
The following parameters were assessed for comparability: time between alcohol abuse and hospital
admission, time between hospital admission and randomization, age, sex, baseline total bilirubin, INR, creatinine, MELD, baseline status of infection and
antibiotic treatment, use of vasopressors, ventilation,
dialysis and steroids use as SOC.

Covariates and Prespeciﬁed
Subgroup Analysis
The statistical plan predeﬁned factors related to standard demographics, selected baseline characteristics,
medical history, regional and geographical site–related
factors, and SOC. Comparisons between treatment
groups according to these predeﬁned criteria were carried out, analyzed, summarized, and reviewed. The following demographic and baseline characteristics were
evaluated: age, sex, baseline MELD score and its components, hepatic encephalopathy grade, and baseline
white blood cell (WBC) count.

Study Populations
The ITT population included all randomized subjects
assigned to the group to which they were randomized,
regardless of actual treatment. The safety population
was deﬁned by actual treatment received by subjects.

LIVER TRANSPLANTATION, Vol. 24, No. 3, 2018

Results
PARTICIPANTS
Between March 2013 and February 2015, 374 patients
were screened at 40 sites in the United States, United
Kingdom, and Australia. Of those screened, 203 subjects met the criteria for enrollment and were randomized to either ELAD (n 5 96) or control (n 5 107)
comprising the ITT population. Also, 171 subjects did
not meet 1 or more of the inclusion or exclusion criteria as detailed in the legend of Fig. 2. The uneven distribution of subjects between ELAD and control is
due to the block randomization by site (blocks of 4, 2
each of ELAD and control). Because individual sites
did not enroll sufﬁcient subjects to fulﬁl 1 or more
complete blocks, there was, by chance, an imbalance of
ELAD and control subjects.
The baseline characteristics of the 203 subjects are
presented in Table 1. The majority of subjects were in
stratum A (n 5 193), with only 10 subjects assigned to

THOMPSON ET AL.

stratum B, therefore both strata were combined and
further analysis will be presented for the total population (n 5 203). There were 13 of 107 control and 15 of
96 ELAD subjects who were diagnosed with sAH
with a conﬁrmatory biopsy. The groups had comparable time between last alcohol intake, hospitalization,
and randomization. Groups had an even distribution
of sex, MELD score (mean, 27.3), bilirubin (mean,
25.1 mg/dL), and subjects who required vasopressor
therapy (38 subjects), with no statistically signiﬁcant
differences. Ventilator support was required in
8 ELAD subjects and 3 control subjects. At baseline, 2
ELAD subjects and no control subjects were on acute
dialysis. The control group had more subjects <35
years old than the ELAD group.
Approximately half of the subjects in both groups
were on steroids and one-third were treated with pentoxifylline at baseline.
There were no observed differences in the use of
steroids between groups at screening, days 1-7, or as
the study progressed.



FIG. 2. Flowchart and disposition of patients during the study until July 2015. Of the 374 subjects screened for the study, 171 did
not meet inclusion criteria or presented with exclusion criteria, most frequently the inability to provide informed consent (n 5 39),
MELD score > 35 (n 5 44), evidence of reduction in total bilirubin of 20% or more in the previous 72 hours (n 5 42), and evidence
of signiﬁcant concomitant disease with expected life expectancy of <3 months (n 5 29). *The ITT population is “as randomized.” Of
the 96 subjects randomized to ELAD, 2 subjects deteriorated and became unstable before ELAD could be initiated; those subjects
did not receive ELAD. One subject randomized to control received ELAD. In a separate safety analysis, the populations were analyzed “as treated.” †During the 91-day follow-up, 1 patient in the ELAD group and 1 in the control group were “lost to follow-up”
and 2 patients in the control group withdrew consent, so the outcome is known in 95 and 104 subjects in ELAD and control. ‡As of
July 2015, using data from the VTI-208 Extension study, the outcome is known for 94 ELAD and 102 Control subjects; 1 ELAD
subject and 3 Control subjects were lost to follow-up and 1 ELAD subject and 2 Control subjects withdrew consent.
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13 (34.2)

0 (0)
2 (5.3)

25 (65.8)
13 (34.2)
22 (57.9)

43.0 6 10.5

12.3 6 10.8

23.7 6 17.7

37 (97.4)
1 (2.6)

MELD  28
(n 5 38)

26
29
3
11 (19.0)
23.8 6 9.4
2.2 6 0.5
0.9 6 0.6
27.8 6 3.8
2.7 6 0.7
143.0 6 90.7
57.9 6 30.9
14.9 6 9.5
19.7 6 4.0
37
27 (46.6)
27 (46.6)

0 (0)
1 (1.7)

33 (56.9)
25 (43.1)
33 (56.9)

36.6 6 5.9

9.7 6 9.1

18.9 6 16.7

55 (94.8)
3 (5.2)

Age < 46.9
years
(n 5 58)

28
12
6
9 (18.4)
24.4 6 6.9
1.9 6 0.5
0.9 6 0.4
26.2 6 3.6
2.6 6 0.6
138.5 6 69.7
65.6 6 46.7
13.9 6 6.2
18.8 6 3.8
28
26 (53.1)
7 (14.3)

0 (0)
2 (4.1)

32 (65.3)
17 (34.7)
25 (51.0)

54.4 6 5.8

9.0 6 5.9

19.7 6 15.7

46 (93.9)
3 (6.1)

Age  46.9
years
(n 5 49)

Prespecified Subgroups Control (n 5 107)

NOTE: Data are given as n (%) or mean 6 SD. Table 1 provides the baseline characteristics of all subjects as well as of the predeﬁned subgroups regarding age and baseline.
MELD. With the exception of a higher ratio of younger patients in the control arm, none of the baseline characteristics reached statistical difference by either unpaired comparison
(t test or Mann-Whitney U test were appropriate) or chi-square analysis for distribution analysis.

Acute AH (group A)
AH superimposed on underlying liver
disease not due to alcohol (group B)
Days between last alcohol
and hospital admission
Days between site admission
and randomization
Age, years
Sex
Males
Females
Subjects with infection and
systemic antibiotics
>2 episodes of dialysis in last week
Intubated
Encephalopathy grade
0
1-2
3-4
On vasopressors
Bilirubin from baseline MELD, mg/dL
INR
Creatinine, mg/dL
MELD
Albumin, g/dL
AST, U/L
ALT, U/L
WBC, 109/L
Liver size ultrasound
Ascites present
On steroids
On pentoxifylline

Baseline Characteristics

ELAD
(n 5 96)

Age < 46.9
years
(n 5 43)

Prespecified Subgroups ELAD (n 5 96)

TABLE 1. Baseline Characteristics
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At baseline, 58 of 96 (60.4%) ELAD and 58 of 107
(54.2%) control (n.s.) subjects were on systemic antibiotics for infection. There were also no signiﬁcant differences between ELAD and controls in this subpopulation
with respect to disease severity based on MELD or age.
The safety population was deﬁned according to
whether subjects actually received either ELAD treatment or SOC because this would best deﬁne the safety
proﬁle of ELAD treatment. This population differed
from the ITT population because 2 subjects randomized to ELAD did not actually receive ELAD treatment, because they became unstable before the therapy
could be initiated and 1 subject randomized to control
inadvertently received ELAD treatment, leading to 95
subjects in the ELAD treatment group and 108 subjects in the control group.

TREATMENT EXPOSURE
Of the 96 subjects randomized to receive ELAD treatment, 45 completed treatment of 120 hours, 37 completed between 72 and 120 hours, 12 received <72
hours of treatment, and 2 became too unstable to initiate. The control subject who received ELAD was
treated for <72 hours. In total, 95 subjects were
exposed to ELAD therapy, of which 13 subjects did
not receive minimum treatment.
There were 50 subjects who did not complete the
protocol-speciﬁed maximum treatment of 120 hours.
These subjects were discontinued due to the following:
clotting (n 5 2), investigator deeming patient too
unstable to continue (n 5 9), adverse event (n 5 18),
futility due to bilirubin increase >25% (n 5 1), subject
withdrawing consent (n 5 1), subject wanting to be
removed from ELAD (n 5 2), need for interruption to
conduct CT scan or dialysis (n 5 2), mechanical issue
(n 5 1), catheter issues (n 5 3), family wanting to proceed with comfort measures only (n 5 1), component
issue (n 5 3), and 7 subjects were discontinued without
documentation that explained why.

OS AND SURVIVAL PROPORTION
IN THE ITT
The OS with a minimum follow-up time of 91 days,
as evaluated according to the statistical plan, was not
different between the groups as depicted in Fig. 3
(HR, 1.03; 95% CI, 0.69-1.53) with 47.9% death rate
in the ELAD group and 47.7% in the control group.
At the time of database lock, 51% of ELAD subjects
and 49.5% of control subjects were alive (Fig. 2).
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The survival proportion at days 28 and 91 was
comparable between the ELAD and control groups,
with 76.0% versus 80.4% and 59.4% versus 61.7%,
respectively.

EFFECT OF ELAD TREATMENT
EXPOSURE ON 91-DAY
MORTALITY
Of the 14 subjects receiving <72 hours of treatment,
including 2 where treatment was not initiated due to
progressive instability at the time ELAD arrived, 10
(71.4%) subjects died within 91 days. Of the 82 subjects completing the minimum treatment of 72 hours
for per protocol analysis, 29 (35.4%) subjects died.
Mortality differed minimally between subjects receiving between 72 and 120 hours (12/37) and completing
120 hours (17/45; 32.4% versus 37.8%).

COVARIATES AND PROSPECTIVE
SUBGROUP ANALYSIS
Analyses of the prespeciﬁed subgroups of baseline age and
MELD greater or less than the baseline medians (46.9
years and 28, respectively) revealed that there were trends
toward worse outcomes in subjects with MELD and/or
age greater than the baseline medians. Conversely, subjects
with MELD and/or age less than the baseline medians
experienced better outcomes (Fig. 4). The majority of the
study population (n = 120) presented with MELD < 28,
in which ELAD (n 5 51) was associated with lower mortality: 29.4% versus 43.5% in the control group (n 5 69;
HR, 0.58; P 5 0.08). Comparison of the baseline characteristics in this subgroup revealed no signiﬁcant differences
between subjects randomized to ELAD versus control
that could have confounded this result (Table 1).
Those with MELD  28 (n 5 83) had a mortality rate
of 68.9% in the ELAD group (n 5 45) versus 55.3% in
the control group (n 5 38; HR, 1.50; P 5 0.15).
Further analysis of the components of MELD that
could be responsible for this effect revealed a trend
toward poor survival in subjects who received treatment with ELAD who had severe kidney damage, as
deﬁned by creatinine > 1.5 mg/dL, and serious coagulopathy, as deﬁned by INR > 2.5. A high creatinine or
high INR predicted a less favorable outcome on
ELAD whereas high bilirubin showed no effect on relative survival between the groups.
In the subgroup of the study population that presented with age <46.9 years (n 5 101), ELAD
(n 5 43) was associated with lower mortality compared
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FIG. 3. The Kaplan-Meier analysis
is given for the ITT population. At
database lock, 46 subjects had died in
the ELAD group and 53 in the control group. Remaining at risk were 49
in the ELAD group and 53 in the
control group.


with the control group (n 5 58): 32.6% versus 44.8%
(HR, 0.63; P 5 0.17). Comparison of the baseline
characteristics revealed no signiﬁcant differences
between ELAD and control subjects that could have
explained this result (Table 1).
In the study population with 46.9 years (n 5 102),
there was a tendency toward higher mortality in
ELAD (n 5 53) versus in control (n 5 49): 60.4% versus 51.0% (HR, 1.35; P 5 0.26).
Although not prespeciﬁed, survival in subjects with
a combination of both MELD < 28 and age < 46.9
years (n 5 59) was signiﬁcantly better in the ELAD
group (n 5 26) than in the control group (n 5 33;
100% versus 73%; P 5 0.006) at 91 days.

STANDARD OF CARE
The 33 of 96 (34.4%) ELAD subjects and 45 of
107 (42.1%) control subjects received a 7-day standard dose >25 mg of prednisone. Documented
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reasons for not administering steroids, such as renal
failure or infection, were more frequent (n.s.) in the
ELAD group; 58 out of 96 (60.4%) ELAD subjects
presented with baseline infection under systemic
antibiotic therapy compared with 58 out of 107
(54.2%) control subjects. Of the subgroup with baseline infection and systemic antibiotic treatment, 30
out of 58 (51.7%) ELAD subjects and 29 out of 58
(50.0%) control subjects were alive at 91 days, indicating a higher mortality than noninfected patients
among both groups.
Survival analyses were run for prednisone use versus
no prednisone use and for infection with antibiotic
treatment versus no infection. The primary end point
analyses showed no difference in outcome of the study
for the overall population.
There was also no correlation between pentoxifylline
or N-acetylcysteine use and outcome. Comparison of
procedures to manage complications did not differ
between groups.
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FIG. 4. The Kaplan-Meier analysis is given for the prespeciﬁed subgroup analysis with respect to age and baseline MELD. (upper
right) The subgroup with age < 46.9 years, at database lock, 14 subjects had died in the ELAD group and 26 in the control group.
Remaining at risk were 29 in ELAD and 32 in the control group. (upper left) The subgroup with age > 47 years, at database lock, 32
subjects had died in the ELAD group and 25 in the control group. Remaining at risk were 20 in the ELAD group and 22 in the
control group. (lower right) The subgroup with MELD < 28, at database lock, 15 subjects had died in the ELAD group and 30 in
the control group. Remaining at risk were 35 in the ELAD group and 37 in the control group. (lower left) The subgroup with
MELD > 28, at database lock, 31 subjects had died in the ELAD group and 21 in the control group. Remaining at risk were 14 in
the ELAD group and 16 in the control group.


In general, there was no evidence that different administration of standard care affected the outcomes between
ELAD and control in the ITT or subgroup analysis.

91 days (P < 0.05). Subjects with alcohol use were
younger and had lower MELD, creatinine, and bilirubin levels at screening and discharge than those without (P < 0.05).

OVERT AND COVERT
ALCOHOL USE

BIOMARKERS

Fewer ELAD subjects had positive postdischarge
PEth than controls (28% versus 52%; P < 0.05). Of 49
subjects with a positive PEth test after discharge, only
14 (28.6%) self-reported alcohol use (P < 0.05); 45 of
49 subjects (91.8%) with positive PEth versus 46 of 71
(64.8%) with no evidence of alcohol use were alive at

ELAD treatment resulted in a signiﬁcant reduction of
total bilirubin compared with controls at all time
points from day 2 to day 7. Signiﬁcantly more ELAD
subjects (56/95, 59%) reached a bilirubin reduction
over 20% compared with controls (25/108, 23%) by
day 7.
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Lille score calculation over that period showed
74.7% were responders (Lille < 0.45) in the ELAD
group versus 47% in the control group (P < 0.01). In
parallel, during the 7-day period, the alkaline phosphatase decreased in the ELAD group from 188 6 110 to
152 6 81 U/L, whereas it increased from 173 6 83 to
178 6 100 U/L in the control group.
None of the other routine clinical chemistry parameters showed signiﬁcant changes.
Concentration of IL1Ra, a key protein involved in
the orchestration of the acute phase response, rose signiﬁcantly during ELAD therapy, while remaining
unchanged in control subjects (Fig. 5).
Concentration of alpha-fetoprotein (a protein secreted
by C3A cells) reached their peak of 884,140 ng/mL
within 7 days, with a median of 200,000 ng/mL. Those
levels remained above 100 ng/mL in all ELAD patients
within 1 month and in 68% of patients within 2 months,
but all had normalized at the end of the study.

SAFETY OF ELAD
The percentage of subjects in each group of the safety
population that experienced TESAEs was similar
between the ELAD (76.8%) and control (69.4%)
groups. The percentage of subjects who experienced
certain subgroups of TESAEs is shown in Table 2.
Deaths occurring during the 91-day study period
were also comparable between groups, with 39 deaths
occurring in the ELAD group and 41 in the control
group. On the basis of the study investigators’ assessments, 2 deaths in the ELAD group were judged to be
related to the interventional treatment: 1 was a precipitation of disseminated intravascular coagulation (DIC)
that occurred in a subject with baseline MELD > 28
and 1 was a catheter insertion–related complication.
The number of subjects experiencing TEAEs were
balanced between the ELAD and control groups,
except for anemia (44% versus 16%, respectively),
thrombocytopenia (35% versus 11%), coagulopathy
(31% versus 12%), and hypotension (31% versus 17%).

Discussion
AH is a serious condition with a high mortality and no
effective treatment. This study enrolled a relatively
large group of subjects with a well-deﬁned clinical
diagnosis of AH. The mean MELD score was 27.3 in
these subjects, suggesting a 3-month mortality of
approximately 50%,(16) highlighting the severity of
liver failure in this study. The study failed its primary
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FIG. 5. The IL1Ra concentrations of a subset of ELAD
(n 5 14) and control patients (n 5 11) is depicted as means and
standard errors. The IL1Ra analysis was conducted on a subset
of VTI- 208 subjects that met the inclusion criteria for the follow-up study, VTL 308 (NCT02612428), which focuses on a
population with lower MELD and age. Subjects were only
included in this subset if they had a full sample set, which
included samples from Baseline, Study Days 3, 5, and 7, as well
as at least 1 sample from a follow-up at either 14 or 28 days.
Although levels were comparable at baseline, the difference
between levels in ELAD versus control subjects was signiﬁcant
(P < 0.05, MWU-test) at study days 3, 5, and 7 (1 week). Also,
in the Wilcoxon signed rank test, IL1Ra levels were elevated
compared with baseline signiﬁcantly at study day 3, 5, and 7 in
ELAD patients (P < 0.05), but not in controls.


and secondary end point in a population with sAH
(Maddrey’s DF > 32) and with a MELD ranging
from 18 to 35 and no upper age limit.
Prospective subgroup analysis for MELD < 28 and
age less than the baseline median showed strong trends
toward improved survival, whereas older patients and
those with higher MELD scores had less favorable
outcomes on ELAD.
Subanalysis of MELD components suggests that
more severe coagulopathy with INR > 2.5 reduced the
tolerance of extracorporeal treatment. Although C3A
cells have been shown to produce clotting factors in
vitro and ex vivo, those effects seem not to outweigh
the complex derangements of coagulation observed in
advanced liver failure, which are not only an expression
of reduced synthesis, but also of increased consumption due to DIC, frequently precipitated by looming
infection. The inability to use citrate for anticoagulation with the ELAD system—due to its negative effect
on the C3A cells—may have contributed to this
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TABLE 2. TESAEs by System Organ Class Reported by More Than 2 ELAD Subjects
System Organ Class Serious Adverse
Events Preferred Term
Blood and lymphatic system disorders
Anemia
Coagulopathy
General disorders and administration site conditions
Multiorgan failure
Hepatobiliary disorders
Ascites
Hepatic failure
Hepatorenal syndrome
Infections and infestations
Sepsis
Nervous system disorders
Hepatic encephalopathy
Renal and urinary disorders
Renal failure
Renal failure acute
Respiratory, thoracic, and mediastinal disorders
Respiratory failure
Vascular disorders
Gastrointestinal hemorrhage

Subjects Reporting at Least 1 Serious Adverse Event
ELAD (n 5 95)

Control (n 5 108)

8 (8.4)
3 (3.2)

6 (5.6)
0 (0.0)

7 (7.4)

10 (9.3)

6 (6.3)
13 (13.7)
3 (3.2)

13 (12.0)
10 (9.3)
9 (8.3)

4 (4.2)

2 (1.9)

8 (8.4)

6 (5.6)

4 (4.2)
6 (6.3)

1 (0.9)
12 (11.1)

5 (5.3)

2 (1.9)

7 (7.4)

6 (5.6)

NOTE: Data are given as n (%). These data reﬂect the safety population (see ﬂowchart in Fig. 2). The number of subjects experiencing system organ class–related serious events and the percentage of subjects is shown. According to Good Clinical Practice Guidelines
for Safety Reporting, the determination of seriousness was based on whether the event met one of the following criteria: life threatening, lead to hospital admission and or prolonged hospitalization, upgraded the subject to intensive care, led to death or continued disability, resulted in congenital/birth defects or the event was serious in the opinion of the investigator. Reported serious events were
reviewed by a blinded DSMB. In case of a disagreement with the investigator’s assessment, the investigator was informed and ﬁnal
assessment required consensus.

problem because heparin has been discussed to be an
anticoagulant of second choice in extracorporeal liver
support in patients prone to bleeding.(17) However, a
recent publication showed that low-dose heparin was
associated with an acceptable beneﬁt/risk proﬁle when
used for extracorporeal liver support even in severely ill
patients with severe acute liver failure.(18) Outcomes
were worse for subjects treated with ELAD whose
MELD scores were 28 due to elevated creatinine
indicating that kidney failure increases the risk while
being treated with ELAD. ELAD cannot remove toxins by ﬁltration or dialysis and thus does not provide
renal support. Because of the lack of this function,
potential beneﬁts of ELAD cannot compensate for the
usual adverse effects of extracorporeal therapy, such as
contact activation and anticoagulation, once a subject
is in renal failure.
Interestingly, the beneﬁcial effects seen in subjects
with MELD scores below the baseline median of 28
seemed to manifest themselves not at the time of treatment, but within the following 2-3 weeks (Fig. 4).
This suggests the primary mechanism of action of
C3A cellular therapy is not secondary organ failure

support such as in extracorporeal albumin dialysis, but
in aiding in recovery of the liver, which is known to
take 2-4 weeks. This is also supported by the fact that
age was a second strong covariate that determined
response to ELAD and liver regeneration is wellknown to decrease with age. One hypothesized mechanism for how C3A cells may aid in recovery is based
on C3A cells supporting the defective acute phase
response in vivo. This is exempliﬁed by the signiﬁcant
IL1Ra elevation in the ELAD group, which was not
seen in controls.
The reduction of bilirubin in the ELAD group
exceeds what can be explained by the dilution in the
extracorporeal circuit, and furthermore, C3A cells in
ELAD have no mechanism to drain bilirubin into the
bile. The parallel reduction of alkaline phosphatase in
the ELAD group versus an increase in the control
group may suggest bile ﬂow can improve while on
ELAD. Although the response measured by the Lille
score, the most validated measure for therapy response
in AH,(19) was signiﬁcantly better in ELAD, it did not
translate into a successful OS beneﬁt, which the
authors interpret as a consequence of the worsening of
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the outcome in nonresponders in the ELAD arm.
Similarly, patients with high MELD scores and of
older age had worse outcomes, diluting a potential survival beneﬁt indicated by more Lille responders.
Although the results of subgroup analyses must be
interpreted with caution, the subgroups according to
MELD, creatinine, and coagulation were in fact prespeciﬁed, interrelated, and seen in large groups, and the
authors applied accepted guidelines in reporting
subgroup analyses.(20) The subgroup analysis related to
age alone was also prespeciﬁed. However, because the
combined subgroup analysis with respect to age and
MELD had not been prespeciﬁed, the authors take the
results of this combined analysis with speciﬁc caution.
Conﬁrming the diagnosis of AH with liver biopsy
in this patient population is not routinely performed in
many centers. Both AASLD guidelines(21) for management of AH as well as recommendations from the
National Institute on Alcohol Abuse and Alcoholism(1) consider using a liver biopsy for AH diagnosis
but recognize the barriers in acquiring a biopsy in this
patient population. Our study did not require liver
biopsy for diagnosis, and it followed the clinical diagnostic criteria put forth by these groups. It is possible
that patients have other underlying diagnoses, but we
would not expect the distribution between the treatment and control groups to be different. Only in 16
and 13 patients in the ELAD and the control groups,
respectively, did the investigator perform a biopsy to
conﬁrm the clinical diagnosis.
The teroids or Pentoxifylline for Alcoholic Hepatitis
(STOPAH) trial showed no beneﬁt in 90-day survival
in steroid-treated patients. Thus, the ﬁndings of our
study gain increasing importance because there is an
unmet need for effective therapy for this highly prevalent, highly mortal hepatic disorder.
Because there were limitations in the study design
associated with the patient heterogeneity and a potential uncertainty of diagnosis in 10%-20% of subjects, a
conﬁrmatory study is underway to investigate the
reproducibility of these observations through the conduct of a prospective, randomized, controlled clinical
study in patients with lower MELD and age (VTL
308-NCT02612428).
If successful, younger patients with AH who do
not respond to medical therapy without renal failure
or severe coagulopathy could undergo cellular therapy. This would allow the donor organ pool considered for early transplantation in AH to be directed
to patients with more advanced coagulopathy or renal
failure.
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